| Literature DB >> 33069671 |
Xueyan Chen1, Chuanbo Ding2, Wencong Liu3, Xinglong Liu1, Yingchun Zhao1, Yinan Zheng1, Ling Dong1, Sadia Khatoon1, Mingqian Hao1, Xiaojuan Peng1, Yue Zhang1, Huiying Chen1.
Abstract
The purpose of this study was to determine whether abscisic acid (ABA) can protect against liver fibrosis induced by thioacetamide (TAA) in vivo by inhibiting apoptosis and inflammatory responses. To this end, three times per week, mice were injected intraperitoneally with TAA (200 mg/kg) for 8 weeks to induce liver fibrosis. After the fourth week of treatment, histological changes, the serum biochemical index, inflammation, and hepatocyte apoptosis factors (e.g., caspase-3, B-cell lymphoma 2 [Bcl-2], Bcl-2-associated X [Bax]) were detected to clarify its underlying mechanism. The results clearly indicated that ABA improves TAA-induced hepatic injury and collagen accumulation in mice. Otherwise, ABA significantly reduced liver fibrosis by regulating caspase-3 and Bcl-2, α-smooth muscle actin, and collagen I. ABA inhibited the nuclear factor kappa B pathway, significantly alleviating oxidative stress and inflammatory cytokines. Therefore, ABA may be a potential therapeutic agent for preventing liver damage.Entities:
Keywords: Abscisic acid; Apoptosis; Inflammation; Liver fibrosis; Thioacetamide
Mesh:
Substances:
Year: 2020 PMID: 33069671 DOI: 10.1016/j.ejphar.2020.173652
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432